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Abstract
Isolated tricuspid valve infective endocarditis is relatively rare. However, the frequency of
tricuspid valve infective endocarditis in the United States is rapidly increasing, mainly
due to the epidemic of intravenous drug use. A medical treatment is the first choice for
this disease; however, surgical intervention is required when the patients suffer from heart
failure, large vegetation, or persistent bacteremia despite appropriate medical treatment.
Several techniques for tricuspid valve reconstruction have been proposed, and their out-
comes have been reported to be good. However, in the cases of severe valve destruction,
tricuspid valve replacement is required. Post-surgical management of drug-induced infec-
tive endocarditis is challenging due to its poor compliance to medication and high rate of
reinfection. There is an ethical controversy as to surgical indication for reinfection induced
by relapse of drug use. In addition, because reoperation for tricuspid valve carries high
risk, there is also a controversy regarding valve choice in drug users.
Keywords: tricuspid valve infective endocarditis, intravenous drug use, surgical
outcomes
1. Introduction
Infective endocarditis carries high mortality and mortality. Murdoch et al. studied 2781 adults
with definite infective endocarditis admitted to 58 hospitals in 25 countries [1]. They reported
that surgical treatment was performed in 48%, and in-hospital mortality was 18%. Neverthe-
less, surgery during the current endocarditis episode was associated with decreased risk of in-
hospital death (odds ratio, 0.56; 95% confidence interval, 0.44-0.69).
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Tricuspid valve infective endocarditis was relatively rare and accounted for 5 to 10% of all
infective endocarditis [2]. In the study of Murdoch et al. which was reported in 2009 [1], tricuspid
valve infective endocarditis was found in 12% of the entire cohort. However, the frequency of
tricuspid valve infective endocarditis is rapidly increasing along with the epidemic of intrave-
nous drug use. Seratnahaei et al. reported that the incidence of tricuspid valve infective endocar-
ditis was 6% between 1999 and 2000, and it markedly increased to 36% between 2009 and 2010
[3]. Also reported history of intravenous drug use increased from 15 to 40%.
2. Surgery for tricuspid valve infective endocarditis
2.1. Epidemiology
The key predisposing factors for tricuspid valve infective endocarditis include intravenous
drug use, cardiac implantable electronic devices, long-term central venous access catheters,
and congenital heart disease [4].
In the study of Murdoch et al. [1], current intravenous drug use was found in 16% of the cohort
of North America, chronic intravenous access accounted was found in 25%, implantable
cardiac devices accounted was found in 12%, and congenital heart disease accounted was
found in 25%.
Moss et al. reported that 41% of injection drug users with bacteremia had the evidence of
endocarditis [5].
Athan et al. performed a prospective cohort study which described a 6.4% incidence of cardiac
device-related infective endocarditis among 2760 patients [6]. There was coexisting valve
involvement in 37.3% patients and predominantly tricuspid valve infection (24.3%). Concom-
itant valve infection was associated with higher mortality than no valve infection (odds ratio,
3.31; 95% confidence interval, 1.71–6.39).
2.2. Indications for surgery
The most recent guidelines from the American Heart Association stated that the surgical inter-
vention is reasonable for patients with certain complications with class IIa recommendations,
and they also stated that it is reasonable to avoid surgery when possible in patients who are
intravenous drug users [7]. The 2015 European Society of Cardiology guidelines for the manage-
ment of infective endocarditis stated that surgery should be considered in the following situa-
tions with class IIa recommendations: [1] right heart failure secondary to severe tricuspid
regurgitation with poor response to diuretic therapy, [2] infective endocarditis caused by organ-
isms that are difficult to eradicate (e.g. persistent fungi) or bacteremia for at least 7 days despite
adequate antimicrobial therapy, and [3] tricuspid valve vegetations >20 mm that persist after
recurrent pulmonary emboli with or without concomitant right heart failure [8].
Hecht et al. followed the clinical course of 121 patients with right-sided infective endocarditis
caused by intravenous drug use, and reported that vegetations greater than 20 mm were
associated with increased mortality [9].
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Kiefer et al. performed a prospective, multicenter study enrolling over 4000 patients with
infective endocarditis and known heart failure status [10]. In-hospital mortality was lower in
the patients undergoing valvular surgery compared with medical therapy alone (20.6 vs.
44.8%, p < 0.001), and 1-year mortality was also lower in patients undergoing surgery com-
pared with medical therapy alone (29.1 vs. 58.4%, p < 0.001).
2.3. Timing of surgery
The early surgical intervention for left-sided infective endocarditis has been well suggested
[7, 11, 12]; however, the surgical indications for right-sided infective endocarditis are not
well defined.
Akinosoglou et al. suggested that the timing of surgical management depends on the follow-
ing factors: [1] cause of endocarditis (e.g. urgent in pacemaker and prosthetic infective endo-
carditis), [2] causative infective factors (e.g. fungal and Staphylococcus aureus), [3] coexistent
left-sided infection, [4] response to antibiotic therapy, [5] toxicity of medical treatment, and [6]
complications of disease (e.g. abscess and increased vegetation size) [13].
Early surgery should be considered if the causative organism is Staphylococcus aureus, which
often results in large vegetations, massive valve destruction, and embolic manifestations [14].
Remadi et al. reported that early surgery was associated with reduced mortality in Staphylo-
coccus aureus infective endocarditis [15].
Taghavi et al. compared the outcomes between surgical management and medical treatment
for tricuspid valve endocarditis [16]. They found that patients treated surgically had clear
blood cultures sooner, defervesced earlier, and demonstrated a complete resolution of vegeta-
tions. They concluded that the early surgery is warranted for patients with tricuspid valve
endocarditis when they are bacteremia and/or systemically infected despite optimal medical
treatment.
In contrast, Gaca et al. reviewed the surgical outcomes for isolated tricuspid valve endocarditis
using the Society of Thoracic Surgeons Database, and reported that patients in the healed
tricuspid valve endocarditis had lower complications rates, shorter overall length of stay, and
a trend toward lower operative mortality compared with active endocarditis [17].
2.4. Tricuspid valve reconstruction
Akinosoglou et al. suggested that, in intravenous drug users who run a high risk of complica-
tions, vegetectomy and valve repair, avoiding artificial materials should be considered as that
can improve late survival rate [13].
Successful surgical intervention requires radical debridement of infected tissue first [4]. In case
of leaflet perforation or small defects localized to one or two leaflets can be repaired by either
direct closure or patch plasty using an autologous pericardial patch [18] (Figure 1).
In case of limited infection on the posterior leaflet, bicuspid valve formation of the tricuspid
valve can be performed by excising the posterior leaflet and mobilizing the anterior and septal
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leaflets [18] (Figure 2). Ghanta et al. reported good mid-term outcomes of suture bicuspidization
of the tricuspid valve [19].
Artificial chordae using expanded polytetrafluoroethylene sutures can be applied after the
resection of infected chordae [20].
Tricuspid annuloplasty is performed either with prosthetic rings or with non-prosthetic suture
annuloplasty such as Kay’s or De Vega’s annuloplasty [13]. Although suture annuloplasty has
an advantage of avoiding prosthetic materials in the setting of infection, several studies
Figure 1. Endocarditic lesion on the anterior leaflet (A), the posterior leaflet (B), or on both (C), anterior and septal
leaflet (D–F) after the excision of the endocarditic lesion, patch plasty, and stabilization of the valve with a tricuspid
annuloplasty ring.
Figure 2. (A) Endocarditic lesion on the posterior leaflet. (B) Excision of the posterior leaflet. (C) Partial mobilization
of the anterior and septal leaflet and preparation of plication sutures. (D) Bicuspid leaflet formation of the valve.
(E) Stabilization of the valve with a tricuspid annuloplasty ring.
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showed that the ring annuloplasty is superior to suture annuloplasty in terms of recurrent
tricuspid regurgitation or reoperation [21–24].
2.5. Tricuspid valve replacement
In case of severe valve destruction, valve replacement is performed using either a mechanical
valve or tissue valve.
Cho et al. compared surgical outcomes of mechanical tricuspid valve replacement (n = 59) and
tissue tricuspid valve replacement (n = 45), and found that there was no difference in long-term
valve-related complications such as thromboembolic or bleeding events [25].
Hwang et al. also reported that there was no difference in long-term survival, cardiac death
rates, and thromboembolic and bleeding complication rates between mechanical and tissue
tricuspid valve replacements [26].
Liu et al. performed a meta-analysis to review the results of mechanical and bioprosthetic
valves in the tricuspid valve position [27]. They did not find difference in survival, reoperation,
or prosthetic valve failure between two valve types.
2.6. Surgical outcomes for tricuspid valve infective endocarditis
The surgical outcomes for tricuspid valve infective endocarditis are listed in Table 1. Overall
good surgical outcomes were reported, and the durability of tricuspid valve reconstruction
was good.
Study Year Number
of pts
Surgical technique Mortality (%) Recurrence
of
regurgitation
Recurrence of infection
Musci
et al. [28]
2007 51 31 reconstructions, 17 tissue
TVR, 3 mechanical TVR
11.3% for
reconstruction,
12.5% for TVR
— 2 patients had
reoperation due to
reinfection after the
tricuspid reconstruction.
Gottardi
et al. [18]
2007 22 18 reconstructions, 3 tissue
TVR, 1 mechanical TVR
0 3 patients
had grade
1–2 TR
2 patients had recurrent
endocarditis, which were
treated conservatively.
Baraki
et al. [29]
2013 33 15 reconstructions,14 tissue
TVR, 4 mechanical TVR
9 2 patients
had grade > 2
TR
3 patients underwent
reoperation for recurrent
endocarditis
Gaca
et al. [17]
2013 910 354 reconstructions,
66 valvectomies, 490 TVR
7.6% for
reconstruction,
12.1% for
valvectomy, 6.3%
for TVR
— —
TVR, tricuspid valve replacement; TR, tricuspid regurgitation.
Table 1. Surgical outcomes for tricuspid valve endocarditis.
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Musci et al. reported a 20-year single institution surgical experience for right-sided infective
endocarditis [28]. They performed 31 tricuspid valve reconstructions and 20 valve replace-
ments. The 30-day, 1-, 5-, 10- and 20-year survival rate after the operation was 96.2, 88.4, 73.5,
70.4 and 70.4%, respectively, for isolated right-sided infective endocarditis. The survival rate
was significantly better than the patients with combined right- and left-sided infective endo-
carditis. Survival was not different between valve reconstruction and replacement.
Gottardi et al. performed 18 tricuspid valve repair and 4 tricuspid valve replacements for
active infective endocarditis, and there was no mortality [18]. During the follow-up, three
patients presented with grade 1–2 tricuspid valve regurgitation after the valve reconstruction.
Baraki et al. reviewed 33 tricuspid valve surgeries for endocarditis, which included 14 tissue
valve replacements, 4 mechanical valve replacements, and 15 tricuspid valve repairs [29].
Thirty-day mortality was 9%, and advanced age, EuroSCORE, and Staphylococcus aureus were
associated with a less long-term survival rate. Residual tricuspid valve regurgitation grade ≥2
was found in two patients.
2.7. Intravenous drug user
Intravenous drug abuse is increasing dramatically in the United States [30]. Of many medical
complications caused by drug use, infective endocarditis is one of the most challenging issues
given the significant risk of acute mortality as well as late recidivism, reinfection, and poor
social situations.
The infection caused by the drug use can be found both on right- and left-sided heart or even
on both sides. Even though the prognosis of right-sided infective endocarditis is better than
left-sided, surgery may be required in at least 25% of patients [31].
The surgical outcomes for drug-induced endocarditis are summarized in Table 2. Overall, the
short-term and long-term survival was not different between drug users and non-drug users;
however, the rates of late reinfection and reoperation are higher in drug users.
The choice of valve prosthesis for intravenous drug users is controversial [32]. Rabkin et al.
reported that the median survival of intravenous drug users was only 3 years, and therefore tissue
valves are justified even for young patients [33]. Kaiser et al. used tissue valves more frequently in
drug users than non-drug users (75 vs. 52%), even though drug users were younger [34].
In the meantime, several previous studies showed that the postoperative survival rate of drug
users is similar to non-drug users [34–37]. That may imply that intravenous drug users receiving
tissue valves will live long enough to require a reoperation for valve degeneration. Given the fact
that the redo surgery for tricuspid valve carries high risk [38], the use of mechanical valve may be
justified for selected patients who can be compliant with anticoagulation. Mechanical tricuspid
valves have a risk of thrombosis with an incidence of ≤3.3% of patient-years [39].
2.8. Reinfection after surgery
Patients with intravenous drug use are high risk of reinfection. The surgical outcomes for redo
tricuspid valve surgery have been reported to be poor.
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Jeganathan et al. reviewed 68 patients who had previous history of tricuspid valve surgery and
underwent reoperations on the tricuspid valve, and in-hospital mortality was 13.2% [38]. They
also reported high incidence of postoperative bleeding, low cardiac output syndrome, stroke,
and renal failure.
Musci et al. reported that 6 out of 79 patients underwent reoperation due to reinfection after
the correction of right-sided active infective endocarditis, and only 1 of them (16.7%) survived
the reoperation [28].
The prognosis of prosthetic valve infection without surgical intervention is dismal. Ivert et al.
reported that 64% of the patients with prosthetic valve endocarditis died, and most deaths
occurred within 3 months of the first evidence of infection [40]. Nevertheless, the surgical
treatment for prosthetic valve endocarditis is also challenging [41].
Luciani et al. performed multicentre study for surgical outcomes for prosthetic valve endocar-
ditis [42]. Among 209 patients who underwent surgery for prosthetic valve endocarditis, the
in-hospital mortality was high (21.5%). Grubitzsch et al. reviewed 149 patients who underwent
redo surgery for prosthetic valve endocarditis [43]. The operative mortality was 12.8%.
Study Year Number of pts Hospital Findings
Shrestha
et al. [35]
2015 536; 41 (8%) were drug users Cleveland clinic Short-term mortality was not different
between drug users and non-drug users;
however, a hazard of death or reoperation
between 3 and 6 months after the operation
was 10 times higher in drug users
compared with non-users.
Kim
et al. [36]
2016 436; 78 (17.9%) were drug
users
Massachusetts General
Hospital and Brigham
and Women’s Hospital
Operative mortality was lower among
drug users; however, overall mortality was
not different. Drug users had higher risk of
valve-related complications principally
because of higher rates of reinfection.
Rabkin
et al. [33]
2012 197; 64 (32.5%) were drug
users
University of
Washington Medical
Center
Survival was lower in drug users than non-
drug users (at 30 days, 1 year, 5 years, and
10 years; 91.2 vs. 93.6%, 77.5 vs. 83.0%, 46.7
vs. 71.1%, and 41.1 vs. 52.0%, respectively,
p = 0.027). Intravenous drug use was an
independent risk factor for diminished
survival (p = 0.03). 8 of 64 (12.5%) of drug
users experienced recurrent infective
endocarditis.
Kaiser
et al. [34]
2007 346; 62 (17.9%) were drug
users
Washington University Long-term survival and perioperative
complications were not different between
drug users and non-drug users; however,
reoperation for recurrent infection was
higher in drug users (17 vs. 5%, p = 0.03).
Carozza
et al. [37]
2006 39 drug-induced infective
endocarditis and 85 non-drug-
induced infective endocarditis
Second University of
Naples
Although hospital and long-term survival
did not significantly differ between two
groups, the rate of recurrence of infection
was higher in drug users.
Table 2. Surgical outcomes for drug-induced infective endocarditis.
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In the setting of high risk of surgical treatment for reinfection, a dilemma exists regarding the
surgical indication for patients who are non-compliant to medical treatment, and develop
reinfection due to relapsing of drug use [44]. There is a controversy as how many chances
surgeons should give to non-compliant patients.
Hull et al. proposed that the patients who have a history of intravenous drug use should be
encouraged to sign a contract agreeing to undergo drug rehabilitation and make a good faith
effort to abstain from substance abuse in the future [45].
3. Conclusions
The incidence of tricuspid valve infective endocarditis is increasing along with the epidemic of
intravenous drug use. Surgical treatment would be necessary when the patients suffer from heart
failure, large vegetation, and persistent bacteremia despite appropriate antibiotic therapy. Tricus-
pid valve reconstruction is desirable as artificial material can be avoided; however, in cases of
severe valve destruction, tricuspid valve replacement is warranted. Management of patients with
intravenous drug users is challenging due to late recidivism, reinfection, and poor social situa-
tions. The operation for reinfection carries high risk. There is an ethical controversy regarding the
surgical indication for reinfection induced by relapse of drug use. Surgeons can play a role by
bringing the problem of epidemic of drug use to public consciousness.
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